Validea Detailed Fundamental Analysis

Validea's guru fundamental report indicates Boston Scientific (BSX) received a 68% rating from Pim van Vliet's Multi-Factor Investor model, which seeks low-volatility stocks with strong momentum and high net payout yields. This score falls below the 80% threshold for 'some interest,' primarily due to neutral performance in the momentum and net payout yield criteria, despite passing market cap and standard deviation tests. Consequently, BSX received a 'FAIL' on the strategy's final rank, suggesting it does not strongly align with this specific quantitative approach for identifying outperforming low-risk equities.

Analysis

Boston Scientific Corporation (BSX) does not meet the quantitative criteria of Pim van Vliet's Multi-Factor Investor model, according to a Validea fundamental report. The model, which seeks to identify outperforming low-risk equities, assigned BSX a score of 68%, falling short of the 80% threshold that typically indicates strategic interest. While the company successfully passed the model's tests for market capitalization and low standard deviation, confirming its low-volatility profile, it failed to demonstrate strength in other key areas. Specifically, BSX received a 'NEUTRAL' rating on both its 'Twelve Minus One Momentum' and 'Net Payout Yield' factors. This mixed performance, where the stock exhibits the desired low-risk characteristic but lacks the required momentum and shareholder return signals, resulted in an overall 'FAIL' on the strategy's final rank, signaling a poor fit for this particular factor-based investment approach.

Key Decisions for Investors

• Investors following quantitative, low-volatility strategies similar to Pim van Vliet's should note that BSX currently fails to qualify due to its neutral momentum and net payout yield characteristics.
• This analysis is strictly factor-based and does not assess BSX's broader business fundamentals; therefore, growth-oriented investors may still find the stock attractive but should not rely on this specific model for validation.
• Shareholders who invested in BSX based on a combined thesis of low risk and strong momentum should re-evaluate their position, as the stock currently appears to satisfy only the low-risk component of that strategy.